We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Gilead Sciences (GILD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of our Medical group, which includes 844 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. GILD is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.91% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that GILD has returned about 6.94% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 4.09% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.
Looking more specifically, GILD belongs to the Medical - Biomedical and Genetics industry, which includes 352 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, this group has gained an average of 2.47% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Gilead Sciences (GILD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of our Medical group, which includes 844 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. GILD is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.91% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that GILD has returned about 6.94% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 4.09% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.
Looking more specifically, GILD belongs to the Medical - Biomedical and Genetics industry, which includes 352 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, this group has gained an average of 2.47% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.